Dr. Richard A. Peterson
Claim this profilePark Nicollet Clinic - Saint Louis Park
Studies Brain Tumor
Studies Small Cell Lung Cancer
7 reported clinical trials
16 drugs studied
Area of expertise
1Brain Tumor
Stage IV
2Small Cell Lung Cancer
Stage IV
Stage I
Stage II
Affiliated Hospitals
Clinical Trials Richard A. Peterson is currently running
Lomustine + Standard Therapy
for Glioblastoma
This phase III trial compares the effect of adding lomustine to standard chemotherapy with temozolomide and radiation therapy versus temozolomide and radiation therapy alone in shrinking or stabilizing newly diagnosed MGMT methylated glioblastoma. MGMT methylated tumors are more likely to respond to temozolomide chemotherapy. Temozolomide is in a class of medications called alkylating agents. It works by damaging the cell's DNA and may kill tumor cells and slow down or stop tumor growth. Lomustine is a chemotherapy drug and in a class of medications called alkylating agents. It damages the cell's DNA and may kill tumor cells. Radiation therapy uses high energy x-ray photons to kill tumor cells and shrink tumors. Adding lomustine to standard chemotherapy with temozolomide and radiation therapy may shrink or stabilize glioblastoma.
Recruiting2 awards Phase 34 criteria
Radiation Therapy vs Observation
for Meningioma
This trial studies if radiation therapy helps prevent the return of grade II meningioma after surgery. Radiation therapy uses powerful x-rays to destroy any leftover cancer cells. The goal is to see if this improves patient outcomes compared to just monitoring them. Radiation therapy has shown success in stabilizing tumor growth and reducing recurrence risk.
Recruiting2 awards Phase 312 criteria
More about Richard A. Peterson
Clinical Trial Related3 years of experience running clinical trials · Led 7 trials as a Principal Investigator · 5 Active Clinical TrialsTreatments Richard A. Peterson has experience with
- Radiation Therapy
- Bevacizumab
- NovoTTF-200A Device
- Clinical Observation
- Prophylactic Cranial Irradiation
- Magnetic Resonance Imaging
Breakdown of trials Richard A. Peterson has run
Brain Tumor
Small Cell Lung Cancer
Meningioma
Gliosarcoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Richard A. Peterson specialize in?
Richard A. Peterson focuses on Brain Tumor and Small Cell Lung Cancer. In particular, much of their work with Brain Tumor has involved Stage IV patients, or patients who are undergoing treatment.
Is Richard A. Peterson currently recruiting for clinical trials?
Yes, Richard A. Peterson is currently recruiting for 5 clinical trials in Saint Louis Park Minnesota. If you're interested in participating, you should apply.
Are there any treatments that Richard A. Peterson has studied deeply?
Yes, Richard A. Peterson has studied treatments such as Radiation Therapy, Bevacizumab, NovoTTF-200A Device.
What is the best way to schedule an appointment with Richard A. Peterson?
Apply for one of the trials that Richard A. Peterson is conducting.
What is the office address of Richard A. Peterson?
The office of Richard A. Peterson is located at: Park Nicollet Clinic - Saint Louis Park, Saint Louis Park, Minnesota 55416 United States. This is the address for their practice at the Park Nicollet Clinic - Saint Louis Park.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.